Next-generation automation is closing the gap between curative science and real-world demand, enabling faster development, ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen receptor (CAR) T-cell administration in patients with relapsed/refractory ...

As demand for precision medicine accelerates, CAR T and CAR Treg cell therapies are emerging as crucial tools in the fight against cancer and autoimmune diseases. For Thomas Fellner, PhD, head of ...

Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant. BioNTech will ...

Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, manufacturing considerations have prompted Lyell Immunopharma to cut staff at its ...

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the automobile manufacturing industry, including Ford (NYSE:F) and its peers. Much ...